Presideo, Verisign partner, gain Medquist as customer
Presideo, Verisign partner, gain Medquist as customerPresideo, a firm specializing in digital identity management in healthcare, and Verisign, a firm concentrating on security infrastructure for e-business, have partnered to provide services to
Presideo, Verisign partner, gain Medquist as customer
Presideo, a firm specializing in digital identity management in healthcare, and Verisign, a firm concentrating on security infrastructure for e-business, have partnered to provide services to the healthcare industry. Verisign will combine its 24/7 managed trust services infrastructure with Presideos identity management products to develop online physician credentialing; biometric authentication; interoperability services; and a policy, legal, and business framework specific to healthcare. Presideo and Verisign will jointly market these security services.
The firms have already sold Medquist, a transcription services vendor owned by Philips, on their joint offering. Medquist will embed Internet security infrastructure and digital certificates into existing products and Medquist.net products.
- Search Again
- Return To HNN Homepage
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.
